Method for providing optimal drug dosage

• US 6,898,455 B2
• Filed: 06/03/2002
• Issued: 05/24/2005
• Est. Priority Date: 10/29/1999
• Status: Expired due to Fees

• Current Assignee: Mclean Hospital (Mass General Brigham, Inc.)
• Original Assignee: Mclean Hospital (Mass General Brigham, Inc.)
• Inventors: Lowen, Steven Bradley, Maas, Luis C. III, Anderson, Carl M., Renshaw, Perry F., Teicher, Martin H.
• Primary Examiner(s): Casler, Brian L.
• Assistant Examiner(s): JUNG, WILLIAM C
• Application Number:
  US10/162,529
• Publication Number:
  US 20020193684A1
• Time in Patent Office: 1,086 Days
• Field of Search: 600/407, 600/411, 600/410, 600/419, 324300-318
• US Class Current: 600/411
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/16 Devices for psychotechnics using teaching or educational appliances G09B1/00 - G09B7/00; Testing reaction times ; Devices for evaluating the psychological state

Abstract

A method for treating attention deficit/hyperactivity disorder (ADHD) includes performing an objective ADHD behavioral assay for a patient, administering a drug to the patient at varying doses, and performing an fMRI on the patient for the varying drug doses to determine an optimal dosage for the patient. The method can further include performing a further objective ADHD behavioral assay after the drug administration.

Claims

1. A method for treating attention deficit/hyperactivity disorder (ADHD), comprising:

performing an objective ADHD behavioral assay for a patient;

administering a drug to the patient at varying doses; and

performing an fMRI on the patient for the varying drug doses to determine an optimal dosage for the patient.

2. The method according to claim 1, further including performing a further objective ADHD behavioral assay after the drug administration.

3. The method according to claim 1, further including performing the objective ADHD behavioral assay using monotonous computerized task.

4. The method according to claim 1, further including performing the objective ADHD behavioral assay using an Optax test.

5. The method according to claim 1, further including administering methylphenidate to the patient.

6. The method according to claim 1, further including performing the fMRI to obtain T2 RT information to assess blood volume changes in a cerebellum of the patient in response to the drug doses.

7. The method according to claim 6, further including selecting a first one of the varying drug doses based upon blood flow levels to the cerebellar vermis of the patient in response to the drug doses.

8. The method according to claim 1, further including performing the fMRI at predetermined times after the administration of the drug.

9. The method according to claim 1, further including screening the patient by evaluating the patient for a predetermined number of ADHD symptoms.

10. The method according to claim 1, further including obtaining a baseline fMRI for the patient.

11. The method according to claim 1, further including administering each of the varying drug doses for about a week.

12. The method according to claim 1, further including plotting a T2 RT change for each of the drug doses from a baseline T2 RT.

13. The method according to claim 12, further including plotting the T2 RT changes versus a baseline objective ADHD test of the patient.

14. The method according to claim 12, further including selecting the optimal one of the varying drug doses corresponding to a largest positive percent change in the T2 RT from baseline.

15. The method according to claim 1, further including

identifying a region of interest (ROI) in the fMRI;

computing median pixel intensity values in the ROI; and

determining a T2 relaxation time from the median pixel intensity values.

16. A method for selecting an optimal drug dosage to treat ADHD, comprising:

performing a first objective ADHD test on a patient;

performing an fMRI on the patient to obtain a baseline T2 RT in the cerebellum;

administering a drug to the patient at a first dosage for a first period of time;

performing an fMRI on the patient to obtain T2 RT information including blood flow changes in the cerebellum in response to the first dosage;

performing a second objective ADHD test on the patient a known time after the administration of the first dose;

administering the drug to the patient at a second dosage for a second period of time;

performing an fMRI on the patient to obtain T2 RT information including blood flow changes in the cerebellum in response to the second dosage;

performing a third objective ADHD test on the patient a known time after administration of the second dose; and

selecting the first or second drug dose to treat ADHD based upon a level of T2 RT change for each of the first and second doses from the baseline T2 RT versus the first objective ADHD test.

17. The method according to claim 16, further including administering methylphenidate as the drug.

18. The method according to claim 16, further including performing the fMRI for the first dosage after the first predetermined time.

19. The method according to claim 16, further including the first objective ADHD test as an Optax test.